Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity
Intra-tumoral MS~RLI and MS~RLI combined with systemic treatment with other agents could provide beneficial antitumor and anti-metastatic effects without the toxic effects of systemic IL-15 agonists. Our findings demonstrate that intra-tumorally administered long-acting IL-15 agonists counter two criticisms of loco-regional therapy: the necessity for frequent injections and the challenge of managing metastases.
Authors
- Rodrigo Fernández (ORCID: https://orcid.org/0000-0003-4619-339X)
- Dimitris Stellas (ORCID: https://orcid.org/0000-0002-7787-3921)
- John A. Hangasky (ORCID: https://orcid.org/0000-0002-8386-3922)
- Daniel V. Santi (ORCID: https://orcid.org/0000-0002-3790-0673)
- George N. Pavlakis (ORCID: https://orcid.org/0000-0002-4027-4036)
- Barbara K. Felber (ORCID: https://orcid.org/0000-0001-8925-8128)
- Sevasti Karaliota
- Gary W. Ashley (ORCID: https://orcid.org/0000-0002-5366-9109)
- Guillermo Hails
Institutions
- Leidos (United States) (US)
- ProLynx (United States) (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Leidos Biomedical Research Inc. (United States)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.3389/fimmu.2024.1458145
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- National Institutes of Health
- University of California, San Francisco
- National Cancer Institute
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco